A five-year study has revealed a stability in global acute kidney injury (AKI)–related mortality rates with differing ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial ...

It also took the spot as the 12th leading cause of disability-adjusted life-years (DALYs), with an age-standardized DALY rate ...

Implementing policy change to advance equity in kidney care requires interdisciplinary support and institutional readiness, ...

Data presented at Kidney Week 2025 showed single subcutaneous administration of megalin-STRIKERs resulted in increased excretion of disease-related solute levels lasting for at least 2 months Dr. Ravi ...

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of ...

Late-breaking presentation of Explore-CKD trial at ASN Kidney Week – – Pivotal Phase 3 Launch-HTN trial featured in the “Best of JAMA and NEJM” session - RADNOR, Pa., ...

VANCOUVER, BC / ACCESS Newswire / November 4, 2025 / American Critical Minerals Corp. (“ American Critical Minerals ” or the” Company “) (CSE:KCLI)(OTCQB:APCOF)(Frankfurt:2P3) is pleased to announce ...

XPHOZAH is the first and only phosphate absorption inhibitor (PAI) approved by the U.S. Food and Drug Administration to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add ...

Nephrologists must capitalize on new therapeutic agents and opportunities to carry on the momentum of the field, according to ...

Over 3.5 years, patients randomized to 4 g of daily fish oil had a 43% lower risk for a composite of serious cardiovascular ...